AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$302.43
+$4.04 (+1.35%) 4:00 PM ET
Pre-market$302.46
+$0.03 (+0.01%) 8:23 PM ET
Prev closePrevC$298.39
OpenOpen$298.39
Day highHigh$302.93
Day lowLow$296.37
VolumeVol338,761
Avg volAvgVol406,837
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$13.15B
P/E ratio
8.35
FY Revenue
$12.15B
EPS
36.24
Gross Margin
27.76%
Sector
Financials
AI report sections
MIXED
RNR
RenaissanceRe Holdings Ltd.
No AI report section text found yet for this symbol.
AI summarized at 3:48 PM ET, 2025-08-20
Volume vs average
Intraday (cumulative)
−12% (Below avg)
Vol/Avg: 0.88×
RSI
54.14(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
-0.02 (Weak)
MACD: -0.03 Signal: -0.01
Short-Term
-0.92 (Weak)
MACD: 5.57 Signal: 6.49
Long-Term
-0.02 (Weak)
MACD: 9.66 Signal: 9.68
Intraday trend score
45.00
LOW32.00HIGH45.00
Latest news
RNR•12 articles•Positive: 1Neutral: 0Negative: 0
PositiveGlobeNewswire Inc.• N/A
VedTechBio® Launches RxAgentAI™ – an Artificial Intelligence and Machine Learning Platform, catering to the decision making and strategic needs of stakeholders in the life sciences industry AND VedTechBio® Announces a Drug Discovery Collaboration with RenaissThera®
VedTechBio, a biopharma-tech company, has launched RxAgentAI, an AI and ML platform for the life sciences industry. It has also announced a drug discovery collaboration with RenaissThera, a biotech company working on metabolic diseases.
RenaissThera is a biotech company focused on developing novel treatments for metabolic diseases, and has partnered with VedTechBio to leverage their AI and computational capabilities, suggesting the company's commitment to innovation and collaboration.
UnknownZacks Investment Research• Zacks Equity Research
Here's Why You Should Hold RenaissanceRe (RNR) Stock for Now
RenaissanceRe (RNR) is expected to benefit from rising premiums, net investment income, and underwriting capabilities.
RNRBROAMBCROOT
UnknownZacks Investment Research• Zacks Equity Research
W.R. Berkley (WRB) Boosts Shareholders' Value Via Several Moves
Improved pricing, expansion of international business, reserving discipline, a solid balance sheet and a prudent capital management policy should help W.R. Berkley (WRB) maintain its streak of dividend hikes and special dividends.
WRBRNRAXSRDN
UnknownZacks Investment Research• Zacks Equity Research
Is First Trust Financials AlphaDEX ETF (FXO) a Strong ETF Right Now?
Smart Beta ETF report for FXO
FXORNRPGRAGO
UnknownZacks Investment Research• Zacks Equity Research
RenaissanceRe (RNR) Up 2% Since Last Earnings Report: Can It Continue?
RenaissanceRe (RNR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RNRFAF
UnknownZacks Investment Research• Zacks Equity Research
Garmin and O-I Glass have been highlighted as Zacks Bull and Bear of the Day
Garmin and O-I Glass are part of the Zacks Bull and Bear of the Day article.
OIGRMNRNRAXS
UnknownZacks Investment Research• Tanuka De
3 Insurance Stocks to Watch on Share Buyback Spree
We focus on AXS, RDN and RNR whose board of directors recently approved new share buyback programs, banking on the confidence that the companies' operational expertise will boost liquidity.
RNRAXSRDN
UnknownZacks Investment Research• Zacks Equity Research
RNR vs. CINF: Which Stock Is the Better Value Option?
RNR vs. CINF: Which Stock Is the Better Value Option?
RNRCINF
UnknownZacks Investment Research• Zacks Equity Research
RenaissanceRe (RNR) Moves to Buy: Rationale Behind the Upgrade
RenaissanceRe (RNR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RNR
UnknownZacks Investment Research• Zacks Equity Research
RenaissanceRe (RNR) Q1 Earnings Beat on Solid Property Segment
RenaissanceRe's (RNR) first-quarter results reflect a solid underwriting performance and improved investment income. A rise in expenses partially offsets its quarterly results.
RLICBWRBRNR
UnknownZacks Investment Research• Zacks Equity Research
Here's What Key Metrics Tell Us About RenaissanceRe (RNR) Q1 Earnings
Although the revenue and EPS for RenaissanceRe (RNR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
RNR
UnknownZacks Investment Research• Zacks Equity Research
RenaissanceRe (RNR) Tops Q1 Earnings and Revenue Estimates
RenaissanceRe (RNR) delivered earnings and revenue surprises of 23.53% and 5.96%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
RNRAFG
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
